Figure 1
AB = baseline, CD = eight weeks follow-up. Axial non-contrast enhanced CT-images in lung and mediastinal window settings show a decrease in size of the primary lung tumor in the right upper lobe (A, C). Also note the decreased short axis of the mediastinal adenopathies (B, D). Regarding the extra-osseous lesions, patient would have been classified according to RECIST 1.1. as partial response.
Figure 2
Sagittal and axial CT-images in bone window setting (Figure 1). The baseline study (A, C) shows no focal lytic or blastic bone lesions. First follow-up CT after eight weeks of treatment with erlotinib (B, D) shows numerous new blastic bone lesions in the spine, ribs and sternum. Misinterpretation of these findings as new metastases would classify this patient as progressive cancer disease.